FEEDS
Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
Cork, Ireland (ots/PRNewswire) - Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Recruitment Ongoing in Europe for Two Tibotec Phase III Clinical Trials Studying TMC278 in Treatment-Naïve HIV-Infected Adults
Cork, Ireland (ots/PRNewswire) - - Once-Daily TMC278 is the Third Anti-HIV Compound to be Developed in Tibotec Virology Portfolio Tibotec Pharmaceuticals is currently recruiting HIV-positive, treatment-naïve adults (or those who have never taken ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
PREZISTA(R) (darunavir) Receives Expanded Marketing Authorisation in the European Union for Treatment-Experienced Adults With HIV-1
Cork, Ireland (ots/PRNewswire) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment-Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naïve Adults With HIV-1
Cork, Ireland, November 27 (ots/PRNewswire) - The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA(R) (darunavir) with low-dose ritonavir as part of ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Cork, Ireland, November 20 (ots/PRNewswire) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI), in ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Cork, Ireland (ots/PRNewswire) - -INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI-Resistant Virus The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
TMC278 Demonstrates Long-Term Efficacy and Tolerability in Treatment-Naïve Adults With HIV
Mexico City, Mexico (ots/PRNewswire) - - Ninety-Six-Week Data on Tibotec Investigational NNRTI Presented at AIDS 2008 New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once-daily, investigational non-nucleoside ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
INTELENCE(TM) (etravirine) Receives Positive Opinion From European Committee for Human Medicinal Products (CHMP) for Treatment of HIV
Cork, Ireland (ots/PRNewswire) - - INTELENCE is the first NNRTI to demonstrate antiviral activity in patients with NNRTI-resistant virus - Tibotec Pharmaceuticals, Ltd. announced today that the Committee for Human Medicinal Products (CHMP) of the ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
New Prezista(R) Phase 3 Study Meets Primary Objective of Non-Inferiority and Secondary Objective of Superiority in Virologic Response vs. Kaletra(R) in Treatment-Experienced HIV Patients
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III Trials
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III Trials
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
New Prezista(R) Phase 3 Study Meets Primary Objective of Non-Inferiority and Secondary Objective of Superiority in Virologic Response vs. Kaletra(R) in Treatment-Experienced HIV Patients
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
TMC125 Can Be Used in Combination with Most Antiretrovirals
Glasgow, Scotland, November 15 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
TMC125 Can Be Used in Combination with Most Antiretrovirals
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Verwendung von TMC125 in Kombination mit den meisten antiretroviralen Therapien möglich
Glasgow, Schottland, November 14 (ots/PRNewswire) - - Auch Kompatibilität mit anderen von HIV/AIDS-Patienten verwendeten Arzneimitteln festgestellt Eine kritische Betrachtung von 17 Studien zu Interaktionen zwischen Arzneimitteln unter ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Drug-Drug Interactions Clinically Manageable With PREZISTA(TM)
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Data Presented at HIV 8 Conference - New studies on the use of PREZISTA(TM), an investigational anti-HIV medication, suggest that it can be co-administered with many common medications ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec verlautbart erweitertes Zugangsprogramm für seinen für die experimentelle Forschung freigegebenen Wirkstoff TMC125
Yardley, Pennsylvania (ots/PRNewswire) - - Das Programm bringt frühen Zugang für ausgewählte HIV-1 infizierte Patienten mit begrenzten Behandlungsoptionen Tibotec Pharmaceuticals Ltd. gab heute bekannt, dass das erweiterte Zugangsprogramm ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
48 Week Data on Investigational Antiretroviral TMC125 From Tibotec
Toronto (ots/PRNewswire) - - TMC125 a Next-Generation NNRTI Tibotec Pharmaceuticals Ltd. presented 48 week efficacy and safety data on TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 16th ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Analysis Provides Additional Data for PREZISTA as Part of HIV Combination Therapy
Toronto (ots/PRNewswire) - Additional safety and efficacy data for PREZISTA(TM) (darunavir) 300mg tablets, an anti-HIV medication, will be presented Tuesday, 15 August, at the 16th International AIDS Conference (AIDS 2006) in Toronto, Canada. ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
FDA erteilt Prezista(TM) als Bestandteil von HIV-Kombinationstherapie Zulassung in den USA
Mechelen, Belgien (ots/PRNewswire) - Tibotec Pharmaceuticals Ltd gab heute bekannt, dass das Unternehmen von der U.S. Food and Drug Administration (FDA) die beschleunigte Zulassung für das Medikament PREZISTA(TM) (Darunavir, TMC114) zur ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Neue Daten über das HIV/AIDS Prüfpräparate-Portfolio von Tibotec
Cork, Irland (ots/PRNewswire) - Von Tibotec Pharmaceuticals Ltd. auf der 13. Conference on Retroviruses and Opportunistic Infections' (CROI) in Denver im US-Bundesstaat Colorado letzte Woche präsentierte Daten bekräftigten das breite Forschungs- ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec reicht in Europa Antrag auf Vermarktungsgenehmigung für Prüf-Proteasehemmer zur HIV-Behandlung TMC114 ein
Cork, Irland (ots/PRNewswire) - - Nach kürzlicher Beantragung der Genehmigung als neues Arzneimittel bei der amerikanischen FDA Tibotec Pharmaceuticals Ltd. gab heute bekannt, dass das Unternehmen bei der Europäische Arzneimittelagentur ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec präsentiert Daten zu 2 HIV-Forschungspräparaten aus Phase 2b auf ICAAC
Washington, D.c. (ots/PRNewswire) - - TMC114 und TMC125 zeigen Aktivität gegen wirkstoffresistentes HIV Im Rahmen der 45. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) vom 16. - 19. Dezember in Washington ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
Tibotec bricht Forschungsstudie mit TMC125 ab
Co Cork, Irland, November 29 (ots/PRNewswire) - - Phase III Zulassungsstudien laufen weiter CO CORK, Irland, November 29 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. gab heute den Abbruch einer Open-Label- Einzelforschungsstudie der ... weiter zur Pressemitteilung von Tibotec Pharmaceuticals Ltd.
